Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676064 | 0.86 | RIPK1 (0.41) | TLR8TLR7TLR9RIPK1HPGD | |
| SCHEMBL674720 | 0.82 | TLR8 (0.49) | TLR8TLR7TLR9HPGDKDM4E | |
| SCHEMBL675470 | 0.81 | KDM4E (0.55) | HPGDKDM4EALDH1A1KIF11KMT2A | |
| SCHEMBL675071 | 0.81 | KIF11 (0.58) | TLR8TLR7HPGDKDM4EALDH1A1 | |
| SCHEMBL674852 | 0.77 | KDM4E (0.43) | TLR8TLR7HPGDKDM4EALDH1A1 | |
| SCHEMBL675477 | 0.77 | RAB9A (0.51) | HPGDKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL675170 | 0.77 | KDM4E (0.42) | TLR8TLR7HPGDKDM4EALDH1A1 | |
| SCHEMBL676133 | 0.77 | RIPK1 (0.41) | TLR8TLR7RIPK1HPGDMCOLN3 | |
| SCHEMBL675507 | 0.74 | ERBB2 (0.47) | TLR8TLR7TLR9RIPK1HPGD | |
| SCHEMBL674944 | 0.69 | HSP90AA1 (0.46) | TLR8TLR7TLR9HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | TLR8 3806/4885TLR7 3780/4885TLR9 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.